VIAL
Compound comparison

Alpha Lipoic Acid IV vs Sermorelin

Alpha Lipoic Acid IV and Sermorelin are both peptide compounds evaluated on Vial: Alpha Lipoic Acid IV is available as a compounded preparation with clinical-trial evidence, and Sermorelin is available as a compounded preparation with clinical-trial evidence.

Vial summary · compiled from public records

At a glance

Alpha Lipoic Acid IV

Category
Peptide
FDA / legal status
Compoundable
Route
0providers on Vial →

Sermorelin

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
27providers on Vial →

Side by side

FieldAlpha Lipoic Acid IVSermorelin
CategoryPeptidePeptide
Brand names
FDA / legal statusCompoundableCompoundable
Evidence tierClinical TrialsClinical Trials
Administration routeSubcutaneous
Compounding accessAvailable through 503A and 503B compounding pharmaciesAvailable through 503A and 503B compounding pharmacies
Providers on Vial0 listed27 listed
Typical price bandVaries by provider$ to $$$

Verified providers offering each

Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+ High Confidence70 to 84 Well Documented50 to 69 Limited ConfidenceUnder 50 Flagged

About each compound

About Alpha Lipoic Acid IV

Intravenous alpha-lipoic acid (ALA) is a both fat- and water-soluble antioxidant with clinically proven efficacy for diabetic neuropathy approved in Germany, used off-label in optimization medicine for neuropathy, metabolic syndrome, heavy metal chelation support, and anti-aging applications. IV delivery achieves plasma concentrations 10–50x higher than oral dosing, enabling therapeutic effects not attainable orally. It regenerates vitamins C, E, and glutathione.

About Sermorelin

A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.

Related compound comparisons

Other comparisons in the same category.

All compound comparisons →